Celcuity (CELC) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Celcuity (CELC) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 33.7% versus a loss of 9.5%. Over five years, VKTX leads with a +374.9% price change compared with +261.4% for CELC. Viking Therapeutics is the larger company by market cap ($3.63 billion vs $3.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | VKTX |
|---|---|---|
| Share price | $65.78 | $28.54 |
| Market cap | $3.22B | $3.63B |
| 1-day change | -7.68% | +0.56% |
| YTD return | -34.05% | -18.87% |
| 1-year return | +33.66% | -9.50% |
| 5-year return | +261.43% | +374.88% |
| EPS (TTM) | $-4.31 | $-4.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-177.04M | $-359.64M |
| 52-week high | $151.02 | $43.15 |
| 52-week low | $45.03 | $25.77 |
| Distance from 52-week high | -56.44% | -33.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +138.54% | +231.85% |
| Average volume | 1.18M | 4.00M |
| Shares outstanding | 48.93M | 127.17M |
| Employees | 155 | 65 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELC has outperformed VKTX by 43.2 percentage points over the past year.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
CELC vs VKTX FAQ
Which is bigger, Celcuity or Viking Therapeutics?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.63B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CELC or VKTX?
CELC returned +33.66% over the past 12 months, compared with -9.50% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and Viking Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Celcuity and Biotechnology: Pharmaceutical Preparations for Viking Therapeutics.